CMPX vs CNSP

Compass Therapeutics, Inc. vs CNS Pharmaceuticals, Inc. — Valuation Comparison 2026

CMPX

Biotechnology
Compass Therapeutics, Inc.
Quality
5.3
out of 10
Value Trap
30
LOW
Price
$2.41
Last close
Models
9/13
Active
VS

CNSP

Biotechnology
CNS Pharmaceuticals, Inc.
Quality
3.6
out of 10
Value Trap
39
LOW
Price
$4.89
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CMPX Fair ValueCMPX Upside CNSP Fair ValueCNSP Upside
Bayesian DCF Intrinsic $0.79 -67.1% $2.41 -50.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.18 -90.4% $1.10 -52.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CMPX vs CNSP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CMPX vs CNSP — Which Stock Is More Undervalued?

CMPX scores higher with a 5.3/10 quality rating vs CNSP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Compass Therapeutics, Inc. (CMPX) and CNS Pharmaceuticals, Inc. (CNSP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CMPX currently trades at $2.41 with a QOC of 5.3/10, while CNSP trades at $4.89 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).